Long-Term Outcomes of Gene Therapy for Hemophilia: Durability and Safety
A comprehensive educational resource designed by leading experts for the global hemophilia community to help you stay abreast of the evolving science and latest clinical advancements in gene therapy in hemophilia.
Through gene therapy treatment, a factor gene is introduced into a virus vector and injected into the patient’s bloodstream with a single infusion. Clinical trials for gene therapy in hemophilia are showing promising results. The safety and efficacy of these trials provide essential information for healthcare professionals, medical students, and patients with hemophilia.
Long-Term Outcomes of Gene Therapy for Hemophilia: Durability and Safety is an interactive webinar developed by leading specialists in this field. This webinar provides education on hemophilia and is a CME activity that can raise awareness of this potentially life-alteringtreatment. It also discusses the importance of clinical trials and how they relate to hemophilia treatment and education.
ISTH convened a panel of world-renowned specialists from the worldwide hemophilia community in early 2019. Their goal was to create a survey that helped identify unmet educational requirements related to gene therapy in hemophilia. The findings show that many people need greater education on the foundations of gene therapy and a better knowledge of gene therapy as a treatment option for hemophilia A and B.
This interactive webinar is just one of many educational resources offered by ISTH. The estimated time to complete the webinar is 30 minutes, and access to it expires on January 27, 2022.
By engaging in this webinar, participants learn the benefits of gene therapy for hemophilia along with the evolving science and clinical advancements. For healthcare professionals working in or interested in the treatment of hemophilia, this information is essential.
With webinars like Long-term Outcomes of Gene Therapy for Hemophilia: Durability and Safety, ISTH helps explain gene therapy fundamentals and while providing up-to-date information to those interested in the latest clinical advances.
Activity Title: Long-term Outcomes: Durability and Safety
Topic: Gene Therapy in Hemophilia
Accreditation Type: AMA PRA Category 1 Credit(s)™
Release Date: January 28, 2021
Expiration Date: January 27, 2022
Estimated Time to Complete Activity: 30 minutes
Long-term Outcomes: Durability and Safety
Gene Therapy in Hemophilia
AMA PRA Category 1 Credit(s)™
January 28, 2021
January 27, 2022
Estimated Time to Complete Activity
Upon completion of the activity, participants should be able to:
- Identify key characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B
- Identify and critically evaluate important safety and efficacy clinical trial outcomes under consideration for gene therapy as a treatment for hemophilia
- Recognize key concerns and unknowns related to the future of gene therapy for hemophilia
Margareth Ozelo, MD, PhD
Prof. Discipline of Hematology and Transfusion Medicine
Department of Internal Medicine
School of Medical Sciences, University of Campinas
Hemocentro UNICAMP, Brazil
Campinas, São Paulo, Brazil
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
This activity is jointly provided by The France Foundation and the International Society on Thrombosis and Haemostasis.
This activity is intended for physicians (hematologists), nurse practitioners, physician assistants and nurses managing patients with hemophilia. The activity is also intended for scientists with an interest in basic, translational, and clinical research in hemophilia around the world.
STATEMENT OF NEED
As development of gene therapy for hemophilia continues into phase 3 clinical trials, and approval of this therapeutic approach is anticipated, it is essential for all members of the hemophilia care team to be knowledgeable and poised for the integration of this new therapeutic approach into clinical practice.
TThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.
Physicians: The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
In accordance with the ACCME Standards for Commercial Support, TFF and the ISTH require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and the ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and the ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Activity Staff Disclosures
The reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
The reviewers, editors, staff, or other members at the International Society of Thrombosis and Haemostasis who control content have no relevant financial relationships to disclose.
The faculty listed below report that they have no relevant financial relationships to disclose:
- Claire McLintock, MBChB, FRACP, FRCPA
- Alok Srivastava, MD, FRACP, FRCPA, FRCP
The faculty listed below report that they have relevant financial relationships to disclose:
- David Lillicrap, MD, FRCPC, receives honoraria for academic consulting from Bioverativ, CSL Behring, and Octapharma Plasma. He receives research funding from Bayer, BioMarin, Bioverative, CSL-Behring, and Octapharma Plasma.
- Johnny Mahlangu, BSc, MBBCh, MMed, FCPath serves on the speakers bureau and does contract research for CSL Berhing, Catalyst Biosciences, Freeline Therapeutics, Novo Nordisk, Roche, Sanofi, Spark, and Takeda.
- K. John Pasi, MChB, PhD, FRCP, FRCPath, FRCPCH, receives research funding from BioMarin GeneR8 programme, uniQure HOPE-B programme, and Sanofi–ATLAS fitusiran program. He receives honoraria from Alnylam, ApcinteX, BioMarin, Catalyst Bio, Chugai, Novo Nordisk, Octapharma Plasma, Pfizer, Roche, Sanofi, Shire, and Sobi.
- Flora Peyvandi, MD, PhD, serves as a consultant for Sanofi and Sobi. She serves on the speakers bureau for Bioverative, Grifols, Roche, Sanofi, Sobi, Spark, and Takeda.
- Glenn F. Pierce, MD, PhD, receives honoraria for academic consulting from BioMarin, Genentech/Roche, Pfizer, St. Jude, and VarmX. He holds leadership positions with Global Blood Therapeutics, NHF MASAC, and World Federation of Hemophilia.
- Steven W. Pipe, MD, serves as a consultant for Apcintex, Bauer, BioMarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics, and uniQure. He does research for Siemens.
- Thierry VandenDriessche, PhD, holds leadership positions with NHF and ISTH. He receives research funding from Pfizer and Takeda. Dr. VandenDriessche receives honoraria from Baxalta, Shire, Takeda, Bayer, Biotest, and Pfizer
Faculty Disclosures–Activity Faculty
The following faculty report that they have relevant financial relationships to disclose:
- Margareth Ozelo, MD, PhD, serves as consultant for BioMarin, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda. She serves on the speakers bureau for Bayer, BioMarin, Novo Nordisk, Roche, and Takeda. Dr. Ozelo conducts contract research for BioMarin, Novo Nordisk, Pfizer, Roche, Sanofi, Spark, and Takeda.
DISCLOSURE OF UNLABELED USE
TFF and ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grants from BioMarin, Freeline Therapeutics Limited, Pfizer Inc, Shire, Spark Therapeutics, and uniQure, Inc.
The France Foundation and International Society of Thrombosis and Haemostasis present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, International Society of Thrombosis and Haemostasis, and the commercial supporter(s) assume no liability for the information herein.
Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.